Efficacy of Neoadjuvant Chemotherapy Combined with Surgery in Patients with Nonsmall Cell Lung Cancer: A Meta-analysis

Overview

Journal Clin Respir J

Specialty Pulmonary Medicine

Date 2024 May 10

PMID 38725310

Authors

Hai-Jun Dong

Cheng-Yan Yang

Affiliations

Soon will be listed here.

Abstract

Introduction: This meta-analysis sought to investigate the effect of neoadjuvant chemotherapy (NACT) combined with surgery in patients with nonsmall cell lung cancer (NSCLC).

Methods: With time span from January 2010 to December 2022, PubMed, Web of Science and Embase, China National Knowledge Infrastructure, and WanFang databases were searched for randomized controlled trials on comparison between NACT combined with surgery and surgery alone in patients with NSCLC. Then a meta-analysis was performed in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines.

Results: A total of 1511 studies were retrieved and 12 were finally included. Meta-analysis results showed that compared with surgery alone, a combination of NACT and surgery was associated with higher treatment response rate (odds ratio, OR = 2.459, 95% confidence interval, CI [1.785, 3.388], P < 0.001), 1-year survival rate (OR = 2.185, 95% CI [1.608, 2.970], P < 0.001), and 3-year survival rate (OR = 2.195, 95% CI [1.568, 3.073], P < 0.001) and lower levels of intraoperative blood loss (standardized mean difference, SMD = -0.932, 95% CI [-1.588, -0.275], P = 0.005) and length of hospital stay (SMD = -0.481, 95% CI [-0.933, -0.028], P = 0.037).

Conclusion: NACT combined with surgery is superior to surgery alone in the treatment of NSCLC and can promote postoperative recovery. Collectively, such combination is a safe and effective treatment for patients with NSCLC.

Citing Articles

Efficacy of neoadjuvant chemotherapy combined with surgery in patients with nonsmall cell lung cancer: A meta-analysis.

Dong H, Yang C Clin Respir J. 2024; 18(5):e13756.

PMID: 38725310 PMC: 11082538. DOI: 10.1111/crj.13756.

References

Miller K, Siegel R, Lin C, Mariotto A, Kramer J, Rowland J . Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4):271-89. DOI: 10.3322/caac.21349. View

Postmus P, Kerr K, Oudkerk M, Senan S, Waller D, Vansteenkiste J . Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv1-iv21. DOI: 10.1093/annonc/mdx222. View

Yendamuri S, Groman A, Miller A, Demmy T, Hennon M, Dexter E . Risk and benefit of neoadjuvant therapy among patients undergoing resection for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2017; 53(3):656-663. PMC: 6018932. DOI: 10.1093/ejcts/ezx406. View

Peer M, Stav D, Cyjon A, Sandbank J, Vasserman M, Haitov Z . Morbidity and mortality after major pulmonary resections in patients with locally advanced stage IIIA non-small cell lung carcinoma who underwent induction therapy. Heart Lung Circ. 2014; 24(1):69-76. DOI: 10.1016/j.hlc.2014.07.055. View

Wong M, McMurry T, Stukenborg G, Francescatti A, Amato-Martz C, Schumacher J . Impact of age and comorbidity on treatment of non-small cell lung cancer recurrence following complete resection: A nationally representative cohort study. Lung Cancer. 2016; 102:108-117. PMC: 5172386. DOI: 10.1016/j.lungcan.2016.11.002. View

Pignon J, Tribodet H, Scagliotti G, Douillard J, Shepherd F, Stephens R . Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008; 26(21):3552-9. DOI: 10.1200/JCO.2007.13.9030. View

Salmon H, Idoyaga J, Rahman A, Leboeuf M, Remark R, Jordan S . Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. Immunity. 2016; 44(4):924-38. PMC: 4980762. DOI: 10.1016/j.immuni.2016.03.012. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Song W, Zhou N, Wang W, Chu X, Liang C, Tian X . Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials. J Thorac Oncol. 2010; 5(4):510-6. DOI: 10.1097/JTO.0b013e3181cd3345. View

10.

Liu J, Blake S, Yong M, Harjunpaa H, Ngiow S, Takeda K . Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. Cancer Discov. 2016; 6(12):1382-1399. DOI: 10.1158/2159-8290.CD-16-0577. View

11.

Goldberg M, Maris C, Hipkiss E, Flies A, Zhen L, Tuder R . Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood. 2007; 110(1):186-92. PMC: 1896112. DOI: 10.1182/blood-2006-12-062422. View

12.

Tang C, Qin S, Wu W, Wu Y, Zhang T . [Efficacy and Potential Application of Neoadjuvant Chemotherapy in Patients with IIIa Stage Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2017; 20(2):100-106. PMC: 5972975. DOI: 10.3779/j.issn.1009-3419.2017.02.04. View

13.

Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Bharat A . NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J Natl Compr Canc Netw. 2021; 19(3):254-266. DOI: 10.6004/jnccn.2021.0013. View

14.

Butts C, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D . Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol. 2009; 28(1):29-34. PMC: 2799232. DOI: 10.1200/JCO.2009.24.0333. View

15.

Boyd J, Hubbs J, Kim D, Hollis D, Marks L, Kelsey C . Timing of local and distant failure in resected lung cancer: implications for reported rates of local failure. J Thorac Oncol. 2009; 5(2):211-4. DOI: 10.1097/JTO.0b013e3181c20080. View

16.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

17.

Dong H, Yang C . Efficacy of neoadjuvant chemotherapy combined with surgery in patients with nonsmall cell lung cancer: A meta-analysis. Clin Respir J. 2024; 18(5):e13756. PMC: 11082538. DOI: 10.1111/crj.13756. View

18.

Yeh J, Marrone K, Forde P . Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer. J Thorac Dis. 2018; 10(Suppl 3):S451-S459. PMC: 5861269. DOI: 10.21037/jtd.2018.01.109. View